0001209191-21-063201.txt : 20211105
0001209191-21-063201.hdr.sgml : 20211105
20211105170026
ACCESSION NUMBER: 0001209191-21-063201
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211104
FILED AS OF DATE: 20211105
DATE AS OF CHANGE: 20211105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pasternak Andy
CENTRAL INDEX KEY: 0001792746
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35238
FILM NUMBER: 211385383
MAIL ADDRESS:
STREET 1: C/O HORIZON THERAPEUTICS PLC
STREET 2: CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
CITY: DUBLIN
STATE: L2
ZIP: D04 C5Y6
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co
CENTRAL INDEX KEY: 0001492426
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 011-353-1-772-2100
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: Horizon Pharma plc
DATE OF NAME CHANGE: 20140919
FORMER COMPANY:
FORMER CONFORMED NAME: HORIZON PHARMA, INC.
DATE OF NAME CHANGE: 20100520
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-04
0
0001492426
Horizon Therapeutics Public Ltd Co
HZNP
0001792746
Pasternak Andy
C/O HORIZON THERAPEUTICS PLC,
70 SAINT STEPHEN?S GREEN
DUBLIN
L2
D02 E2X4
IRELAND
0
1
0
0
EVP and Chief Business Officer
Ordinary Shares
2021-11-04
4
M
0
23251
29.52
A
53523
D
Ordinary Shares
2021-11-04
4
S
0
5484
110.64
D
48039
D
Ordinary Shares
2021-11-04
4
S
0
6336
111.47
D
41703
D
Ordinary Shares
2021-11-04
4
S
0
2706
112.44
D
38997
D
Ordinary Shares
2021-11-04
4
S
0
5650
113.54
D
33347
D
Ordinary Shares
2021-11-04
4
S
0
2728
114.49
D
30619
D
Ordinary Shares
2021-11-04
4
S
0
7264
115.51
D
23355
D
Stock Option (Right to Buy)
29.52
2021-11-04
4
M
0
23251
0.00
D
2029-10-31
Ordinary Shares
23251
23251
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.985 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.005 to $111.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 to $112.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.07 to $114.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.24 to $115.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option is fully vested and exercisable.
/s/ Miles W. McHugh, Attorney-in-Fact
2021-11-05